Ramot at Tel Aviv University

CEO Keren Primor Cohen oversees Ramot's commercialization strategy and investment committee. The office evaluates roughly 100 invention disclosures annually, selecting those with the clearest path to patent and commercial viability. Actual company formation and follow-on funding decisions involve the university's licensing team and external venture partners (per the firm's public disclosures, 2024).

Life sciences accounts for the plurality of Ramot's patent filings, with notable density in neurodegenerative diseases, oncology, and immunology. Key historical out-licenses include patents underlying Copaxone (multiple sclerosis) and Azilect (Parkinson's), both multibillion-dollar drugs. Current activity also includes digital-health and medical-device IP from TAU's engineering and medical faculties.

TAU Ventures, launched in September 2024, is a separate early-stage venture fund that invests in companies spun out of Tel Aviv University research. Unlike Ramot — which handles patent filing, licensing, and company formation — TAU Ventures provides dedicated venture capital from an independent fund structure. The two entities coordinate on deal flow but operate with distinct investment committees.